天然产物研究与开发 ›› 2018, Vol. 30 ›› Issue (5): 870-874.doi: 10.16333/j.1001-6880.2018.5.022

• 开发研究 • 上一篇    下一篇

高乌甲素磷脂复合物纳米粒的制备、表征及药动学研究

徐凯1*,魏永鸽2   

  1. 1黄河科技学院,郑州 450005;2郑州铁路职业技术学院,郑州 450052
  • 出版日期:2018-06-04 发布日期:2018-06-04

Lappaconitine Phospholipids Complex Nanoparticles:Preparation,Characterization and Pharmacokinetic Study

XU Kai1*, WEI Yong-ge2
    

  1. 1Huanghe Science and Technology College,Zhengzhou 450005,China; 2Zhengzhou Railway Vocational & Technical College,Zhengzhou 450052,China
  • Online:2018-06-04 Published:2018-06-04

摘要: 采用溶剂挥发法制备高乌甲素磷脂复合物,薄膜超声法制备高乌甲素磷脂复合物固体脂质纳米粒,并考察基本理化性质。SD大鼠分别灌胃给予高乌甲素及其磷脂复合物固体脂质纳米粒,比较药动学特征及生物利用度。结果表明,高乌甲素磷脂复合物固体脂质纳米粒平均粒径为(224.37±1.93)nm,Zeta电位为(-6.14±0.09)mV,包封率为(85.08±1.84)%。体外释药符合Weibull模型。药动学结果显示,Tmax,Cmax,AUC0~tAUC0~?均具有统计学意义(P<0.05或P<0.01),口服吸收生物利用度提高了2.58倍。因此,高乌甲素磷脂复合物固体脂质纳米粒可有效提高高乌甲素的口服吸收生物利用度。

关键词: 高乌甲素, 包封率, 固体脂质纳米粒, 生物利用度

Abstract: Solvent evaporation method was adopted to prepare lappaconitine phospholipids complex,and thin-film ultrasonic method was used to prepare its solid lipid nanoparticles.The basic physicochemical properties of lappaconitine phospholipids complex solid lipid nanoparticles were also studied.The pharmacokinetics and bioavailability were compared after oral administration of lappaconitine and its phospholipids complex solid lipid nanoparticles.The results showed that particle size,zeta potential and encapsulation efficiency of lappaconitine phospholipids complex solid lipid nanoparticles were (224.37±1.93) nm,(-6.14±0.09) mV and (85.08±1.84)%,respectively.The pharmacokinetic results showed that Tmax, Cmax, AUC0~t, AUC0~?had statistical significance (P<0.05 or P<0.01),and the bioavailability was enhanced by 2.58 times.Therefore,lappaconitine phospholipids complex solid lipid nanoparticles could enhance the bioavailability significantly.

Key words: Lappaconitine, encapsulation efficiency, solid lipid nanoparticles, bioavailability

中图分类号: 

R944.9